HOME >> MEDICINE >> NEWS
Esophageal capsule technology proves as effective as endoscopy

ORLANDO (November 1, 2004)--Researchers in a multi-center pivotal trial of M2A© Esophageal Capsule Endoscopy (Given Imaging, Yoqneam, Israel) found that this new technology is comparable to upper GI endoscopy for the detection of severe esophageal problems.

The researchers studied 82 patients, including 73 patients with gastroesophageal reflux and 9 patients undergoing surveillance for Barrett's esophagus, a pre-cancerous condition found in up to thirteen percent of GERD patients. Individuals with Barrett's are at an increased risk of developing esophageal adenocarcinoma.

Patients in the study ingested the esophageal capsules in a supine position and subsequently were placed under conscious sedation for an upper GI endosocpy. The investigators interpreting the videos from the esophageal capsules were blinded to the results of the traditional endscopy, and vice versa.

Of the 82 patients, 55 had positive findings on upper GI endoscopy. The esophageal capsule identified esophageal abnormalities in 51 of the 55 patients. The sensitivity of the esophageal capsule for detecting Barrett's was 97 percent and the specificity was 100%. Investigators reported no side effects or ingestion difficulties in any of the 82 patients.

The investigators conclude that the esophageal capsule is convenient, safe and sensitive for visualization of esophageal disorders.


'"/>

Contact: Malaika Hilliard
mhilliard@porternovelli.com
202-973-5896
American College of Gastroenterology
1-Nov-2004


Page: 1

Related medicine news :

1. Biological Markers Found That Correlate To Esophageal Cancer Treatment Success
2. Combination Therapy Improves Chances Of Surviving Esophageal Cancer
3. Study shows M2A capsule endoscopy improves clinical outcomes in IBD patients
4. Swallowing a tiny imaging capsule aids in diagnosis of obscure gastrointestinal bleeding
5. Self-assembled nano-capsules resemble bacterial cell walls
6. Growing new blood vessels with a timed-release capsule of growth factor is a promising treatment for heart bypass patients, finds NHLBI study
7. Time-released capsule delivers growth factor to improve coronary bypass surgery
8. Yale technology translates to sonic golf training tool
9. New self-help technology set to combat eating disorders
10. PENN begins clinical trial of newest technology to treat thoracic aortic aneurysms
11. Computer memory, MRI technology benefit from student research at UH

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Esophageal capsule technology proves effective endoscopy

(Date:5/24/2013)... The British Menopause Society and Women,s Health Concern have ... to provide clarity around the role of HRT, the ... the society,s flagship title, Menopause International , published ... HRT has changed from being branded the "elixir of ... be used in certain circumstances. Since the publication of ...
(Date:5/24/2013)... Today marks the launch of Destination ... , The redesigned and enhanced Itinerary Builder will ... on their computer or mobile device that they can ... allows users to fill in their date of arrival ... their choice of vacation packages, accommodations, restaurants, and things ...
(Date:5/24/2013)... Wixom, MI (PRWEB) May 24, 2013 ... recent Cute Baby Photo Contest. Lindsey Willis of Olathe, ... Cuties-brand diapers from DiaperBuys. Second prize was a ... Heather Tacher, North Las Vegas, Nev.; and third prize, ... Texas. , The contest was run through the company’s ...
(Date:5/24/2013)... 2013 Wednesday, 15th May 2013 | 10am ... to access webinar playback: http://bit.ly/10Rt0ZH , Ongoing regulatory ... markets. Across the globe and particularly in Europe, a number ... M&A activity . For dealmakers, understanding how the likes of ... Tax’ affects your corner of the market will give you ...
(Date:5/24/2013)... San Diego, CA (PRWEB) May 24, 2013 ... informing consumers today of the latest update involving ... Zithromax and Zmax SR (azithromycin) can allegedly ... Canadian Broadcasting Company reported on May 17, 2013* ... and Drug Administration in warning that Zithromax can ...
Breaking Medicine News(10 mins):Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:DiaperBuys.com Announces Photo Contest Winners 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 3Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 2Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 3Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 4
(Date:5/24/2013)... YORK , May 24, 2013 In accordance ... Rules and Rule 14e-1 of the United States Exchange Act, ... its original offer for Elan Corporation (NYSE: ELN). ... Limited ("Royalty Pharma") made an offer for the entire of ... Corporation, plc ("Elan") (the "Original Offer").  On ...
(Date:5/23/2013)... , May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... been named the 2013 Life Science Firm of the Year ... (TCM).  Vanda was honored at the TCM,s 25 th ... , Maryland.  The Tech Awards Celebration recognizes the leaders and ... Maryland and the surrounding regions. ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
Cached News: